Immunization Status May Be Unknown…But the Level of Protection Shouldn't Be

Postexposure Prophylaxis for Tetanus

According to the Centers for Disease Control and Prevention (CDC), tetanus leads to death in about 1 in 10 cases.1 For more information, recommendations, and guidelines, visit the CDC Advisory Committee on Immunization Practices (ACIP).

Like most vaccines, tetanus vaccine can take time to build efficacy but can protect for years.2 HyperTET S/D, along with wound cleaning and debridement, provides immediate protection.2 This allows the vaccine the time needed to establish active immunity for your patients in high-risk situations, such as:

  • Those whose immunization status is unknown

    • Immigrants and visitors from other countries where tetanus toxoid vaccination is not mandatory3
    • Patients who were born prior to vaccination series being mandatory2,4
  • Patients with common injuries that can carry a risk of tetanus (eg, puncture wounds or soil contamination of open cuts)2
  • Intravenous (IV) drug users4,5

Immediate Protection

HyperTET S/D contains high titers of tetanus antibodies for postexposure prophylaxis, providing rapid immune protection for up to 21 days. According to the CDC, the use of a tetanus immune globulin such as HyperTET S/D may, if promptly administered, reduce the potentially life-threatening risk of tetanus when administered concomitantly with the tetanus vaccine.1,6

Safety Is a Priority6

  • HyperTET S/D is mercury (thimerosal) free and latex free
  • HyperTET S/D has Food and Drug Administration (FDA) labeling for removal of pathogenic prions that may cause transmissible spongiform encephalopathies in humans

    • Studies of the HyperTET S/D manufacturing process demonstrated that TSE clearance is achieved during the Pooled Plasma to Effluent III Fraction Process (6.7 log10). These studies provide reasonable assurance that low levels of CJD/vCJD agent infectivity, if present in the starting material, would be removed
  • HyperTET S/D offers tamper-evident packaging and incorporates UltraSafe® Needle Guards to help protect the healthcare professional from needle-stick injuries
  • HyperTET S/D is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products

Dosing Recommendations6

HyperTET Dosing Recommendations

Product Information6

HyperTET Product Information

HyperTET® S/D (tetanus immune globulin [human]) is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain.

HyperTET S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HyperTET S/D should be given only if the expected benefits outweigh the risks.

Slight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare. In the course of routine injections of large numbers of persons with immunoglobulin, there have been a few isolated occurrences of angioneurotic edema, nephrotic syndrome, and anaphylactic shock after injection. Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after tetanus immune globulin (human) administration.

HyperTET S/D is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Please see HyperTET S/D full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


  1. Centers for Disease Control and Prevention (CDC). Vaccines and immunizations: Tetanus (lockjaw) vaccination. CDC website. http://www.cdc.gov/vaccines/vpd-vac/tetanus/default.htm. Updated February 3, 2016. Accessed April 27, 2016.
  2. Centers for Disease Control and Prevention (CDC). Epidemiology and prevention of vaccine-preventable diseases. CDC website. http://www.cdc.gov/vaccines/pubs/pinkbook/tetanus.html. Updated September 8, 2016. Accessed April 27, 2016.
  3. Centers for Disease Control and Prevention. Update on Adult Immunization Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep. 1991;40(RR-12):1-52.
  4. Talan DA, Abrahamian FM, Moran GJ, et al. Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds. Ann Emerg Med. 2004;43(3):305-314.
  5. Centers for Disease Control and Prevention. Tetanus among injection-drug users—California, 1997. MMWR Morb Mortal Wkly Rep. 1998; Mar 6;47(8):149-51.
  6. HyperTET® S/D (tetanus immune globulin [human]) prescribing information. Grifols Therapeutics Inc. January 2014.